NEW YORK, Feb.24 (GenomeWeb News) - In an agreement with non-profit CHDI, Cellumen will build a cellular model of Huntington's disease as the foundation of neurotoxicity profiling panel to characterize pre-clinical candidate models, Cellumen said yesterday.

The collaboration is expected to last about a year, Robert Pacifici of CHDI told GenomeWeb News.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.